Literature DB >> 26039827

Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients.

Nuno Laranjeira1, Jorge Fonseca1, Tânia Meira2, João Freitas2, Sara Valido1, Jorge Leitão3.   

Abstract

BACKGROUND: Inflammatory Bowel Disease is known for its extra intestinal manifestations, the oral cavity is no exception.
OBJECTIVES: The aim of this study was to evaluate the association between Inflammatory Bowel Disease and oral mucosa lesions and symptoms, and complementary to evaluate their possible relation with oral hygiene, smoking habits, drug therapy, duration and activity of the disease.
METHODS: Patients were selected from the Gastroenterology Clinic of a Portuguese tertiary referral hospital. This sample consisted of 113 patients previously diagnosed with ulcerative colitis or Crohn's disease along with a control group of 58 healthy individuals that were accompanying the study group patients to their appointments. Clinical interviews and clinical examinations were performed for data collection.
RESULTS: The patients in the study group were more affected by oral symptoms (P=0.011), and showed a trend towards a higher incidence of oral mucosal lesions, even though statistical significance was not reached (8.8% versus 3.4% in the control group; P=0.159). Patients in active phase were the most affected. No differences were detected between Crohn's disease and ulcerative colitis, or concerning smoking habits. The corticosteroid and immunosuppressant therapy seemed to increase the incidence of oral symptoms (P=0.052). The oral mucosa lesions increased and the oral symptoms decreased over the course of the disease, however without statistical significance.
CONCLUSION: Oral mucosa's lesions and oral symptoms were positively associated with Inflammatory Bowel Disease, mainly during disease activity periods and conceivably, associated with corticosteroid and immunosuppressant therapy.

Entities:  

Mesh:

Year:  2015        PMID: 26039827     DOI: 10.1590/S0004-28032015000200006

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  8 in total

1.  Oral Manifestations of Inflammatory Bowel Diseases: Two Case Reports.

Authors:  Manoela Seadi Pereira; Maria Cristina Munerato
Journal:  Clin Med Res       Date:  2016-02-10

Review 2.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Multidisciplinary management: Inflammatory bowel disease.

Authors:  T Thomas; J S Chandan
Journal:  Br Dent J       Date:  2017-01-13       Impact factor: 1.626

Review 4.  The impact of inflammatory bowel disease on oral health.

Authors:  J S Chandan; T Thomas
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

Review 5.  Prevalence of Oral Lesions and Correlation with Intestinal Symptoms of Inflammatory Bowel Disease: A Systematic Review.

Authors:  Dorina Lauritano; Elisa Boccalari; Dario Di Stasio; Fedora Della Vella; Francesco Carinci; Alberta Lucchese; Massimo Petruzzi
Journal:  Diagnostics (Basel)       Date:  2019-07-15

6.  Taste Changes in Patients with Inflammatory Bowel Disease: Associations with PROP Phenotypes and polymorphisms in the salivary protein, Gustin and CD36 Receptor Genes.

Authors:  Melania Melis; Mariano Mastinu; Giorgia Sollai; Danilo Paduano; Fabio Chicco; Salvatore Magrì; Paolo Usai; Roberto Crnjar; Beverly J Tepper; Iole Tomassini Barbarossa
Journal:  Nutrients       Date:  2020-02-04       Impact factor: 5.717

Review 7.  Oral manifestations serve as potential signs of ulcerative colitis: A review.

Authors:  Chunyu Li; Yuqi Wu; Yulang Xie; You Zhang; Sixin Jiang; Jiongke Wang; Xiaobo Luo; Qianming Chen
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

8.  Oral health and salivary function in ulcerative colitis patients.

Authors:  Ariana Goldinova; Christopher Xw Tan; Gerd Bouma; Marjolijn Duijvestein; Henk S Brand; Nanne K de Boer
Journal:  United European Gastroenterol J       Date:  2020-09-02       Impact factor: 4.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.